We therefore, investigated the in vivo effects of runcaciguat in three different CKD models in which proteinuria is driven not only by hypertension but also by diabetes and obesity, namely in angiotensin-treated rats (SD-ANG), in renin transgenic (RenTG) rats supplemented with L-NAME, and in Zucker diabetic fatty (ZDF) rats. Here, ANG is linked to obesity disorder.